Brief: Olema Oncology Announces FDA Clearance Of Investigational New Drug Application For OP-3136
09/12/2024 12:15
Dec 9 (Reuters) - Olema Pharmaceuticals Inc OLMA.O :
* OLEMA ONCOLOGY ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL
NEW
DRUG APPLICATION FOR OP-3136, A POTENT KAT6 INHIBITOR
* OLEMA PHARMACEUTICALS INC - PHASE 1 CLINICAL TRIAL FOR
OP-3136
TO START EARLY 2025
Source text: ID:nGNX8Vj6ws
Further company coverage: OLMA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Olema Pharmaceuticals
See all newsOlema Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs